Phase I trial of combined recombinant interleukin-2 with levamisole in patients with advanced malignant disease.

Call, T G; Creagan, E T; Frytak, S; Buckner, J C; van Haelst-Pisani, C; Homburger, H A; Katzmann, J A

Call, T G; Creagan, E T; Frytak, S; Buckner, J C; van Haelst-Pisani, C; Homburger, H A; Katzmann, J A.

Affiliation

Call TG; Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905.

Am J Clin Oncol ; 17(4): 344-7, 1994 Aug.

Article in En | MEDLINE | ID: mdl-8048398

Subject(s)

Interleukin-2/therapeutic use; Levamisole/therapeutic use; Neoplasms/therapy; Adolescent; Adult; Aged; Cytotoxicity, Immunologic; Female; Fever/etiology; Humans; Interleukin-2/administration & dosage; Interleukin-2/adverse effects; Levamisole/administration & dosage; Levamisole/adverse effects; Lymphocyte Activation; Lymphocyte Subsets; Male; Middle Aged; Nausea/etiology; Neoplasms/immunology; Pruritus/etiology; Recombinant Proteins/administration & dosage; Recombinant Proteins/adverse effects; Recombinant Proteins/therapeutic use

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Levamisole / Interleukin-2 / Neoplasms Type of study: Etiology_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Clin Oncol Year: 1994 Type: Article

Search on Google

XML

PubMed Links